JP7330994B2 - 治療用ナノ生物学的組成物による訓練免疫の促進 - Google Patents

治療用ナノ生物学的組成物による訓練免疫の促進 Download PDF

Info

Publication number
JP7330994B2
JP7330994B2 JP2020545063A JP2020545063A JP7330994B2 JP 7330994 B2 JP7330994 B2 JP 7330994B2 JP 2020545063 A JP2020545063 A JP 2020545063A JP 2020545063 A JP2020545063 A JP 2020545063A JP 7330994 B2 JP7330994 B2 JP 7330994B2
Authority
JP
Japan
Prior art keywords
nanobiological
composition
glycero
patient
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020545063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504446A5 (https=
JPWO2019103998A5 (https=
JP2021504446A (ja
Inventor
モルダー，ウィレム
オチャンド，ジョルディ
ファヤド，ザヒ
ネテア，ミハイ
ヨーステン，レオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of JP2021504446A publication Critical patent/JP2021504446A/ja
Publication of JP2021504446A5 publication Critical patent/JP2021504446A5/ja
Publication of JPWO2019103998A5 publication Critical patent/JPWO2019103998A5/ja
Priority to JP2023130072A priority Critical patent/JP7772748B2/ja
Application granted granted Critical
Publication of JP7330994B2 publication Critical patent/JP7330994B2/ja
Priority to JP2025187368A priority patent/JP2026015394A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nuclear Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020545063A 2017-11-21 2018-11-20 治療用ナノ生物学的組成物による訓練免疫の促進 Active JP7330994B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023130072A JP7772748B2 (ja) 2017-11-21 2023-08-09 治療用ナノ生物学的組成物による訓練免疫の促進
JP2025187368A JP2026015394A (ja) 2017-11-21 2025-11-06 治療用ナノ生物学的組成物による訓練免疫の促進

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589054P 2017-11-21 2017-11-21
US62/589,054 2017-11-21
PCT/US2018/061935 WO2019103998A2 (en) 2017-11-21 2018-11-20 Promoting trained immunity with therapeutic nanobiologic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023130072A Division JP7772748B2 (ja) 2017-11-21 2023-08-09 治療用ナノ生物学的組成物による訓練免疫の促進

Publications (4)

Publication Number Publication Date
JP2021504446A JP2021504446A (ja) 2021-02-15
JP2021504446A5 JP2021504446A5 (https=) 2023-05-23
JPWO2019103998A5 JPWO2019103998A5 (https=) 2023-05-23
JP7330994B2 true JP7330994B2 (ja) 2023-08-22

Family

ID=66630773

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020545063A Active JP7330994B2 (ja) 2017-11-21 2018-11-20 治療用ナノ生物学的組成物による訓練免疫の促進
JP2023130072A Active JP7772748B2 (ja) 2017-11-21 2023-08-09 治療用ナノ生物学的組成物による訓練免疫の促進
JP2025187368A Pending JP2026015394A (ja) 2017-11-21 2025-11-06 治療用ナノ生物学的組成物による訓練免疫の促進

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023130072A Active JP7772748B2 (ja) 2017-11-21 2023-08-09 治療用ナノ生物学的組成物による訓練免疫の促進
JP2025187368A Pending JP2026015394A (ja) 2017-11-21 2025-11-06 治療用ナノ生物学的組成物による訓練免疫の促進

Country Status (7)

Country Link
US (4) US20200261591A1 (https=)
EP (1) EP3713548A4 (https=)
JP (3) JP7330994B2 (https=)
CN (1) CN111971028A (https=)
AU (2) AU2018370828B2 (https=)
CA (1) CA3082830A1 (https=)
WO (1) WO2019103998A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4014967A1 (en) 2016-04-29 2022-06-22 Icahn School of Medicine at Mount Sinai Targeting the innate immunesystem to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
US20230266321A1 (en) * 2020-06-25 2023-08-24 Icahn School Of Medicine At Mount Sinai Live cell engagement assay
CN118459539B (zh) * 2021-03-19 2026-01-06 生物治疗探索股份有限公司 用于调节训练免疫的化合物及其使用方法
IT202100014747A1 (it) * 2021-06-07 2022-12-07 Consiglio Nazionale Ricerche Derivati sterolici come nuovi ligandi del recettore dectina-1 nel trattamento terapeutico di patologie correlate a tale recettore
CA3222851A1 (en) 2021-06-22 2022-12-29 Roy VAN DER MEEL Nucleic acid containing nanoparticles
WO2023192956A2 (en) * 2022-03-31 2023-10-05 Icahn School Of Medicine At Mount Sinai Sphingolipid-loaded nanobiologics for immune regulation
JP2025518282A (ja) 2022-06-03 2025-06-12 バイオ－トリップ ベーフェー 核酸送達のための多価分子に基づく脂質ナノ粒子

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130045161A1 (en) 2009-10-09 2013-02-21 Signablok, Inc. Methods and compositions for targeted imaging
WO2016154544A1 (en) 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2017024312A1 (en) 2015-08-06 2017-02-09 Autotelic Llc Phospholipid-cholesteryl ester nanoformulations and related methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101096386A (zh) * 2007-06-05 2008-01-02 复旦大学 Dectin-1与热休克蛋白Hsp60聚合物及其编码核酸和应用
CN101903018B (zh) * 2007-10-17 2012-09-05 韩国科学技术院 用于递送核酸基因的ldl样阳离子纳米微粒、其制备方法以及使用其递送核酸基因的方法
CN105903029A (zh) * 2007-12-12 2016-08-31 大学健康网络 高密度脂蛋白样肽磷脂支架（“hpps”）纳米颗粒
WO2012026712A2 (ko) * 2010-08-23 2012-03-01 주식회사 강스템홀딩스 Ｎｏｄ２의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물
KR20160093012A (ko) * 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
CN106714836A (zh) * 2015-06-05 2017-05-24 H·李·莫菲特癌症中心研究有限公司 Gm‑csf/cd40l疫苗和检查点抑制剂联合治疗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130045161A1 (en) 2009-10-09 2013-02-21 Signablok, Inc. Methods and compositions for targeted imaging
WO2016154544A1 (en) 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2017024312A1 (en) 2015-08-06 2017-02-09 Autotelic Llc Phospholipid-cholesteryl ester nanoformulations and related methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Curr. Treat. Options in Oncol.，2015年，Vol.16:26，p.1-14
Nanomedicine: Nanotechnology, Biology, and Medicine，2016年，Vol.12，p.81-103

Also Published As

Publication number Publication date
JP7772748B2 (ja) 2025-11-18
CN111971028A (zh) 2020-11-20
AU2018370828B2 (en) 2024-11-21
CA3082830A1 (en) 2019-05-31
EP3713548A2 (en) 2020-09-30
AU2018370828A1 (en) 2020-06-04
US20200261591A1 (en) 2020-08-20
WO2019103998A3 (en) 2019-08-22
EP3713548A4 (en) 2021-06-23
US20250268839A1 (en) 2025-08-28
US20200253884A1 (en) 2020-08-13
JP2023145781A (ja) 2023-10-11
US20230355537A1 (en) 2023-11-09
WO2019103998A2 (en) 2019-05-31
JP2021504446A (ja) 2021-02-15
JP2026015394A (ja) 2026-01-29
AU2025201252A1 (en) 2025-03-13

Similar Documents

Publication Publication Date Title
JP7772748B2 (ja) 治療用ナノ生物学的組成物による訓練免疫の促進
US12414968B2 (en) Compositions comprising bacterially derived minicells and methods of using the same
JP6727237B2 (ja) 血液がん及び固形腫瘍の治療のための併用療法
JP7796707B2 (ja) 治療用ナノバイオロジー組成物での訓練された免疫の阻害
WO2016073348A1 (en) Modified paramagnetic nanoparticles for targeted delivery of therapeutics and methods thereof
CN114222564A (zh) 与具有粘附粒子的红细胞有关的组合物和方法
US12337033B2 (en) Encapsulated glycolipid antigens for treatment of neoplastic diseases
JP2025518126A (ja) がんの治療のための同種異系低免疫生体模倣型ナノ小胞
HK40056270A (en) Encapsulated glycolipid antigens for treatment of neoplastic diseases
HK40045237A (en) Compositions comprising bacterially derived minicells and methods of using the same
KR20190019121A (ko) 종양 내 정맥 형성 촉진제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230515

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230809

R150 Certificate of patent or registration of utility model

Ref document number: 7330994

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150